Newsletter registration

Austria.
Where Your Profits Grow Sky High.

APEIRON Biologics given green light for market approval

Hans Loibner, Apeiron CEO © Apeiron

The development of dinutuximab beta originally began at the Clinical Cancer Research Institute of St. Anna Children’s Hospital in Vienna and was extended to encompass numerous clinical studies throughout Europe and abroad.

In 2011, Apeiron acquired commercial rights to the project, and then led efforts to win market approval in cooperation with academic groups. More than 1,000 patients have been treated up until now. In September 2016, Apeiron EUSA Pharma acquired an exclusive license to the global commercial rights to dinutuximab beta.

The CHMP recommendation issued on March 24, 2017 will be presented to the European Commission by the EMA. The European Commission will issue a formal decision on the approval of dinutuximab beta within the next two months.

Neuroblastoma is the third most frequent malignant tumor afflicting children. The tumors arise from cells of so-called autonomic nervous system. The apparent cause is that cells do not sufficiently mature in their development phase and then begin to reproduce themselves later in an unrestrained manner. About one out of every 5,000 children suffers from this illness. One third of the tumors already occur in children’s first year.

 

About APEIRON Biologics AG

Apeiron is a private biotech company in Vienna, Austria developing innovative projects in the field of immune-oncology..

For more information: www.apeiron-biologics.com

 

Share on Facebook Share on Facebook Share on Twitter Share on Twitter

Testimonials

Events

Meet us at events, seminars and trade shows - worldwide.

  • Panel discussion: Opportunities for expanding your business in Carinthia/Austria

    13.09.2017 / 10:00, Celje Fairm Hall „Celjanka“, Slovenia

  • How to Set up a company in Austria

    28.09.2017, Bratislava, Slovakia

Austria Map

Find the perfect location for your company

Storage and distribution for Eastern Europe is more economical from Vienna than from Prague or Budapest. Because shipping business between the individual reform nations is barely developed, whereas neary every Eastern destination is serviced from Vienna several times a week.

Hewlett Packard Austria

Logo
More testimonials

news from the business location Austria

TRA 2018 is looking for projects and ideas for its new Interactive Zone!

The Transport Research Arena will take place in Vienna, Austria, from 16 - 19th April 2018. The Interactive Zone offers the opportunity to present projects, research results and pilots
in addition to the usual conference and the exhibition. Submissions for this Interactive Zone can still be received until 15th September 2017.

The Albert Patent Bot Checks It Out

Do you have a robot on your team? Perhaps you even have one that can tell jokes? The Austrian Patent Office does. Albert Patent Bot is the name of the digital brand consultant supporting startups with respect to trademark protection. Albert is the very first chat bot in the Austrian public sector and chats with people in Facebook Messenger generously shares his know-how, researches into brands, responds to questions and also tells a physicist joke.

More news All blog posts